Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Google Cloud and Nokia will integrate Google's GEMINI model into Nokia's Assurance Center.
2026-06-22
Google Cloud and Nokia will integrate Google's GEMINI model into Nokia's Assurance Center.
Back
Other News
2026-06-22
According to AXIOS: U.S. diplomats say the focus of the negotiations with Iran is a de-escalation mechanism in Lebanon and the implementation of the ceasefire agreement.
According to AXIOS: U.S. diplomats say the focus of the negotiations with Iran is a de-escalation mechanism in Lebanon and the implementation of the ceasefire agreement.
2026-06-22
China's National Medical Products Administration approved Eli Lilly Nederland B.V.'s class-1 innovative drug elacestrant tosylate tablets (brand INLURIYO) for adults with locally advanced or metastatic estrogen receptor–positive (ER+), HER2–negative,
China's National Medical Products Administration approved Eli Lilly Nederland B.V.'s class-1 innovative drug elacestrant tosylate tablets (brand INLURIYO) for adults with locally advanced or metastatic estrogen receptor–positive (ER+), HER2–negative, ESR1‑mutant breast cancer previously treated with endocrine therapy. Approval covers use as monotherapy and in combination with abemaciclib for the same population, giving Eli Lilly market access in China for an endocrine‑therapy–resistant ER+/HER2– indication.
Chat with us
, powered by
LiveChat